2041 completed, 726 terminated, 605 recruiting, 452 unknown. 4565 Phase 1, 1632 Phase 2.
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-10-28 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-11-02 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-08-11 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-07-27 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
Showing 20 of 4565. Sign in to see all of them.
Multiple Myeloma (1192) · Lymphoma (1069) · Lymphoma, Non-Hodgkin (963) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (837) · Leukemia, Lymphocytic, Chronic, B-Cell (794) · Lymphoma, Large B-Cell, Diffuse (673) · Lymphoma, Follicular (608) · Recurrence (530) · Lymphoma, Mantle-Cell (518) · Leukemia (500) · Leukemia, Myeloid, Acute (458) · Hodgkin Disease (437) · Burkitt Lymphoma (436) · Lymphoma, B-Cell (429) · Lymphoma, B-Cell, Marginal Zone (364)
Immune System Diseases (4533) · Hemic and Lymphatic Diseases (4525) · Immunoproliferative Disorders (4524) · Neoplasms by Histologic Type (4502) · Neoplasms (4236) · Lymphatic Diseases (3605) · Hematologic Diseases (2734) · Lymphoma (1764) · Pathological Conditions, Signs and Symptoms (1503) · Pathologic Processes (1492) · Leukemia, Lymphoid (1491) · Disease Attributes (1403) · Paraproteinemias (1364) · Cardiovascular Diseases (1348)
Cyclophosphamide (452) · Dexamethasone (367) · Rituximab (365) · Lenalidomide (258) · fludarabine (255) · Bortezomib (187) · fludarabine phosphate (168) · Vincristine (149) · Calcium Dobesilate (147) · Cytarabine (127) · venetoclax (125) · Etoposide (124) · Melphalan (124) · Doxorubicin (122) · Prednisone (122)
National Cancer Institute (NCI) (287) · M.D. Anderson Cancer Center (150) · Memorial Sloan Kettering Cancer Center (83) · City of Hope Medical Center (74) · Celgene (66) · Fred Hutchinson Cancer Center (64) · Mayo Clinic (56) · Novartis Pharmaceuticals (54) · Hoffmann-La Roche (47) · Baylor College of Medicine (46) · GlaxoSmithKline (46) · AbbVie (44) · Dana-Farber Cancer Institute (42) · Janssen Research & Development, LLC (41) · Washington University School of Medicine (38)
United States (3026) · China (713) · France (316) · Spain (311) · Australia (271) · Canada (270) · United Kingdom (266) · Italy (240) · Germany (230) · Japan (153) · South Korea (153) · Israel (99) · Netherlands (99) · Belgium (92) · Poland (88)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 32499241, PMID 35622074, PMID 41429239, PMID 19238148, PMID 28054442, PMID 32770353, PMID 33883258, PMID 34780125, PMID 36100310, PMID 37022569, PMID 39319495, PMID 39813680, PMID 24615776, PMID 24615777, PMID 28803351, PMID 32596842, PMID 32632956, PMID 32705923, PMID 32823563, PMID 34687939, PMID 34889384, PMID 36536403, PMID 37192741, PMID 37486616, PMID 37981564, PMID 39563886, PMID 40195173, PMID 40226119, PMID 40802906, PMID 19451441, PMID 19949018, PMID 20028764, PMID 20188202, PMID 20882050, PMID 21816833, PMID 22002018, PMID 22045986, PMID 22510871, PMID 23886836, PMID 24055823, PMID 24265828, PMID 24443277, PMID 24615778, PMID 24782509, PMID 25317870, PMID 25319501, PMID 25381051
2023 (75), P30CA033572 (44), 2015 (36), 2016 (35), P30CA015704 (34), 2018 (30), 2019 (30), 2017 (26), P30CA015083 (25), 2014 (24), U01CA076576 (22), 2025 (20), P30CA016672 (19), P30CA006973 (18), U01CA097452 (16)